A novel serum metabolome score for breast cancer diagnosis

References

• DeSantis CE, Bray F, Ferlay J, et al. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Prev Biomarkers. 2015;24:1495–1506.
   PubMed Web of Science ®Google Scholar
• Asiago VM, Alvarado LZ, Shanaiah N, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010;70:8309–8318.
   PubMed Web of Science ®Google Scholar
• Nagrath D, Caneba C, Karedath T, et al. Metabolomics for mitochondrial and cancer studies. Biochim Biophys Acta Bioenerg. 2011;1807:650–663.
   Web of Science ®Google Scholar
• Armitage EG, Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. Pharmaceut Biomed Anal. 2014;87:1–11.
   PubMed Web of Science ®Google Scholar
• Bujak R, Struck-Lewicka W, Markuszewski MJ, et al. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal. 2015;113:108–120.
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Yan G, et al. Mass spectrometry‐based metabolomics: applications to biomarker and metabolic pathway research. Biomed Chromatogr. 2016;30:7–12.
   PubMed Web of Science ®Google Scholar
• Kouremenos KA, Johansson M, Marriott PJ. Advances in gas chromatographic methods for the identification of biomarkers in cancer. J Cancer. 2012;3:404–420.
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Wang P, et al. Modern analytical techniques in metabolomics analysis. Analyst. 2012;137:293–300.
   PubMed Web of Science ®Google Scholar
• Seidel A, Brunner S, Seidel P, et al. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control. Br J Cancer. 2006;94:1726.
   PubMed Web of Science ®Google Scholar
• Chen J, Hou W, Han B, et al. Target-based metabolomics for the quantitative measurement of 37 pathway metabolites in rat brain and serum using hydrophilic interaction ultra-high-performance liquid chromatography–tandem mass spectrometry. Anal Bioanal Chem. 2016;408:2527–2542.
   PubMed Web of Science ®Google Scholar
• Falegan OS, Ball MW, Shaykhutdinov RA, et al. Urine and serum metabolomics analyses may distinguish between stages of renal cell carcinoma. Metabolites. 2017;7:6.
   PubMed Web of Science ®Google Scholar
• Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS One. 2013;8:e73076.
   PubMed Web of Science ®Google Scholar
• Struck-Lewicka W, Kordalewska M, Bujak R, et al. Urine metabolic fingerprinting using LC–MS and GC–MS reveals metabolite changes in prostate cancer: a pilot study. J Pharm Biomed Anal. 2015;111:351–361.
   PubMed Web of Science ®Google Scholar
• Zhu J, Djukovic D, Deng L, et al. Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring. Anal Bioanal Chem. 2015;407:7857–7863.
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Yan G, et al. Metabolomics in diagnosis and biomarker discovery of colorectal cancer. Cancer Lett. 2014;345:17–20.
   PubMed Web of Science ®Google Scholar
• Günther UL. Metabolomics biomarkers for breast cancer. Pathobiology. 2015;82:153–165.
   PubMed Web of Science ®Google Scholar
• Jobu K, Sun C, Yoshioka S, et al. Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer. Biol Pharm Bull. 2012;35:639–642.
   PubMed Web of Science ®Google Scholar
• Rasmuson T, Björk GR. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncol. 1995;34:61–67.
   PubMed Web of Science ®Google Scholar
• La S, Cho J, Kim J-H, et al. Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients. Anal Chim Acta. 2003;486:171–182.
   Web of Science ®Google Scholar
• Ye N, Liu C, Shi P. Metabolomics analysis of cervical cancer, cervical intraepithelial neoplasia and chronic cervicitis by 1H NMR spectroscopy. Eur J Gynaecol Oncol. 2015;36:174–180.
   PubMed Web of Science ®Google Scholar
• Struck-Lewicka W, Kaliszan R, Markuszewski MJ. Analysis of urinary nucleosides as potential cancer markers determined using LC–MS technique. J Pharm Biomed Anal. 2014;101:50–57.
   PubMed Web of Science ®Google Scholar
• Shulaev V. Metabolomics technology and bioinformatics. Brief Bioinform. 2006;7:128–139.
   PubMed Web of Science ®Google Scholar
• Weckwerth W. Metabolomics: an integral technique in systems biology. Bioanalysis. 2010;2:829–836.
   PubMed Web of Science ®Google Scholar
• Trygg J, Gullberg J, Johansson AI, et al. Extraction and GC/MS analysis of the human blood plasma metabolome. Anal Chem. 2005;77:8086–8094.
   PubMed Web of Science ®Google Scholar
• Omran MM, Rashed RE, Darwish H, et al. Development of a gas chromatography‐mass spectrometry method for breast cancer diagnosis based on nucleoside metabolomes 1‐methyl adenosine, 1‐methylguanosine, and 8‐hydroxy‐2ʹ‐deoxyguanosine. Biomed Chromatogr. 2020;34:e4713.
   PubMed Web of Science ®Google Scholar
• Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165:216–224.
   PubMed Web of Science ®Google Scholar
• Oakman C, Tenori L, Biganzoli L, et al. Uncovering the metabolomic fingerprint of breast cancer. Int J Biochem Cell Biol. 2011;43:1010–1020.
   PubMed Web of Science ®Google Scholar
• Raftery DM, Pan Z, Gu H. Breast cancer biomarkers and identification methods using NMR and gas chromatography-mass spectrometry. Google patent number US8980637B2. 2015.
   Google Scholar
• Woo HM, Kim KM, Choi MH, et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women’s cancers. Clin Chim Acta. 2009;400:63–69.
   PubMed Web of Science ®Google Scholar
• Eldin EEMN, El-Readi MZ, Eldein MMN, et al. 8-hydroxy-2ʹ-deoxyguanosine as a discriminatory biomarker for early detection of breast cancer. Clin Breast Cancer. 2019;19:e385–e393.
   PubMed Web of Science ®Google Scholar
• Berstein L, Poroshina T, Kovalenko I, et al. Serum levels of 8-hydroxy-2ʹ-deoxyguanosine DNA in patients with breast cancer and endometrial cancer with and without diabetes mellitus. Bull Exp Biol Med. 2016;161:547–549.
   PubMed Web of Science ®Google Scholar
• Chen F, Xue J, Zhou L, et al. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem. 2011;401:1899.
   PubMed Web of Science ®Google Scholar
• Dutertre M, Lambert S, Carreira A, et al. DNA damage: RNA-binding proteins protect from near and far. Trends Biochem Sci. 2014;39:141–149.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhao BS, He C. Nucleic acid modifications in regulation of gene expression. Cell Chem Biol. 2016;23:74–85.
   PubMed Web of Science ®Google Scholar
• Kuo H-W, Chou S-Y, Hu T-W, et al. Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients. Mutat Res/Genet Toxicol Environ Mutagen. 2007;631:62–68.
   PubMed Web of Science ®Google Scholar
• Guo C, Li X, Wang R, et al. Association between oxidative DNA damage and risk of colorectal cancer: sensitive determination of urinary 8-hydroxy-2′-deoxyguanosine by UPLC-MS/MS analysis. Sci Rep. 2016;6:32581.
   PubMed Web of Science ®Google Scholar